NCT00500786View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

April 30, 2007

Conditions
Essential Hypertension
Interventions
BIOLOGICAL

CYT006-AngQb

Sponsors
All Listed Sponsors
lead

Cytos Biotechnology AG

INDUSTRY